Your browser doesn't support javascript.
loading
Characterizing Infections in Two Epidemic Waves of SARS-CoV-2 Omicron Variants: A Cohort Study in Guangzhou, China.
Qu, Lin; Xie, Chunyan; Qiu, Ming; Yi, Lina; Liu, Zhe; Zou, Lirong; Hu, Pei; Jiang, Huimin; Lian, Huimin; Yang, Mingda; Yang, Haiyi; Zeng, Huiling; Chen, Huimin; Zhao, Jianguo; Xiao, Jianpeng; He, Jianfeng; Yang, Ying; Chen, Liang; Li, Baisheng; Sun, Jiufeng; Lu, Jing.
Afiliação
  • Qu L; School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
  • Xie C; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Qiu M; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Yi L; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Liu Z; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Zou L; School of Basic Medicine and Public Health, Jinan University, Guangzhou 510632, China.
  • Hu P; School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
  • Jiang H; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Lian H; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Yang M; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Yang H; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Zeng H; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Chen H; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Zhao J; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Xiao J; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • He J; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Yang Y; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Chen L; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Li B; School of Public Health, Southern Medical University, Guangzhou 510515, China.
  • Sun J; Guangdong Provincial Institution of Public Health, Guangzhou 511430, China.
  • Lu J; Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
Viruses ; 16(4)2024 04 22.
Article em En | MEDLINE | ID: mdl-38675989
ABSTRACT

BACKGROUND:

After the adjustment of COVID-19 epidemic policy, mainland China experienced two consecutive waves of Omicron variants within a seven-month period. In Guangzhou city, as one of the most populous regions, the viral infection characteristics, molecular epidemiology, and the dynamic of population immunity are still elusive.

METHODS:

We launched a prospective cohort study in the Guangdong Provincial CDC from December 2022 to July 2023. Fifty participants who received the same vaccination regimen and had no previous infection were recruited.

RESULTS:

90% of individuals were infected with Omicron BA.5* variants within three weeks in the first wave. Thirteen cases (28.26%) experienced infection with XBB.1* variants, occurring from 14 weeks to 21 weeks after the first wave. BA.5* infections exhibited higher viral loads in nasopharyngeal sites compared to oropharyngeal sites. Compared to BA.5* infections, the XBB.1* infections had significantly milder clinical symptoms, lower viral loads, and shorter durations of virus positivity. The infection with the BA.5* variant elicited varying levels of neutralizing antibodies against XBB.1* among different individuals, even with similar levels of BA.5* antibodies. The level of neutralizing antibodies specific to XBB.1* determined the risk of reinfection.

CONCLUSIONS:

The rapid large-scale infections of the Omicron variants have quickly established herd immunity among the population in mainland China. In the future of the COVID-19 epidemic, a lower infection rate but a longer duration can be expected. Given the large population size and ongoing diversified herd immunity, it remains crucial to closely monitor the molecular epidemiology of SARS-CoV-2 for the emergence of new variants of concern in this region. Additionally, the timely evaluation of the immune status across different age groups is essential for informing future vaccination strategies and intervention policies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carga Viral / Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carga Viral / Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2024 Tipo de documento: Article